Pharming Group N.V. income statement

In fiscal 2025, Pharming Group N.V. reported revenue of $376m, up 26.6% on the year before, operating income of $25.8m (a 6.9% margin) and net income of $2.9m, or $0.04 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Pharming Group N.V.: income statement, annual
Fiscal year	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	189	212	199	206	245	297	376
Cost of revenue	24	24	21	18	25	35	46
Gross profit	165	189	178	188	220	262	331
Research and development	32	39	70	53	69	83	100
Operating income	68	76	14	18	−5	−9	26
Interest expense	13	6	6	5	6	9	11
Income before tax	52	44	23	15	−12	−8	13
Income tax	12	6	7	1	−1	3	10
Net income	41	38	16	14	−11	−12	3
Diluted EPS	$0.60	$0.55	$0.23	$0.19	−$0.16	—	$0.04
Diluted shares (average)	67m	68m	70m	71m	73m	79m	75m
EBITDA	73	82	16	20	−4	−7	27

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: PHAR vs SVA MNKD vs PHAR MGTX vs PHAR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Pharming Group N.V.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Pharming Group N.V.